Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The price of Nektar Therapeutics (NASDAQ: NKTR) closed at $55.97 in the last session, up 1.54% from day before closing price of $55.12. In other words, the price has increased by $1.54 from its previous closing price. On the day, 0.85 million shares were traded. NKTR stock price reached its highest trading level at $57.99 during the session, while it also had its lowest trading level at $55.01.
Ratios:
We take a closer look at NKTR’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.24 and its Current Ratio is at 4.24. In the meantime, Its Debt-to-Equity ratio is 1.96 whereas as Long-Term Debt/Eq ratio is at 1.70.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on June 24, 2025, Reiterated its Buy rating but revised its target price to $120 from $6.50 previously.
On June 24, 2025, BTIG Research reiterated its Buy rating and also lowered its target price recommendation from $60 to $100.
Jefferies Upgraded its Hold to Buy on April 11, 2025, while the target price for the stock was maintained at $2.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 09 ’25 when ROBIN HOWARD W sold 6,666 shares for $46.69 per share. The transaction valued at 311,214 led to the insider holds 49,342 shares of the business.
ROBIN HOWARD W bought 6,666 shares of NKTR for $311,205 on Sep 09 ’25. On Sep 04 ’25, another insider, Zalevsky Jonathan, who serves as the Chief R&D Officer of the company, sold 1,721 shares for $33.52 each. As a result, the insider received 57,693 and left with 17,462 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NKTR now has a Market Capitalization of 1064469504 and an Enterprise Value of 1060335779840. For the stock, the TTM Price-to-Sale (P/S) ratio is 17.00 while its Price-to-Book (P/B) ratio in mrq is 12.93. Its current Enterprise Value per Revenue stands at 16938.271 whereas that against EBITDA is -7831.772.
Stock Price History:
The Beta on a monthly basis for NKTR is -0.97, which has changed by 1.7236009 over the last 52 weeks, in comparison to a change of 0.12121439 over the same period for the S&P500. Over the past 52 weeks, NKTR has reached a high of $66.92, while it has fallen to a 52-week low of $0.43. The 50-Day Moving Average of the stock is 2.82%, while the 200-Day Moving Average is calculated to be 137.44%.
Shares Statistics:
According to the various share statistics, NKTR traded on average about 1.01M shares per day over the past 3-months and 708540 shares per day over the past 10 days. A total of 19.65M shares are outstanding, with a floating share count of 18.60M. Insiders hold about 2.18% of the company’s shares, while institutions hold 50.02% stake in the company. Shares short for NKTR as of 1760486400 were 1731971 with a Short Ratio of 1.71, compared to 1757894400 on 1607714. Therefore, it implies a Short% of Shares Outstanding of 1731971 and a Short% of Float of 9.28.
Earnings Estimates
The market rating for Nektar Therapeutics (NKTR) is a result of the insights provided by 3.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$2.59, with high estimates of -$2.59 and low estimates of -$2.59.
Analysts are recommending an EPS of between -$7.97 and -$7.97 for the fiscal current year, implying an average EPS of -$7.97. EPS for the following year is -$10.97, with 3.0 analysts recommending between -$9.18 and -$12.12.
Revenue Estimates
According to 7 analysts,. The current quarter’s revenue is expected to be $10.3M. It ranges from a high estimate of $12.5M to a low estimate of $6.9M. As of. The current estimate, Nektar Therapeutics’s year-ago sales were $29.18MFor the next quarter, 7 analysts are estimating revenue of $9.81M. There is a high estimate of $12.5M for the next quarter, whereas the lowest estimate is $6M.
A total of 6 analysts have provided revenue estimates for NKTR’s current fiscal year. The highest revenue estimate was $45.9M, while the lowest revenue estimate was $40M, resulting in an average revenue estimate of $43.08M. In the same quarter a year ago, actual revenue was $98.43MBased on 8 analysts’ estimates, the company’s revenue will be $40.93M in the next fiscal year. The high estimate is $52M and the low estimate is $24M.
